Article
IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution.
Cancer medicine - 1 Jun 2020
Rodriguez Erika F, De Marchi Federico, Lokhandwala Parvez M, Belchis Deborah, Xian Rena, Gocke Christopher D, Eshleman James R, Illei Peter, Li Ming-Tseh
Abstract excerpt
BACKGROUND: Selective IDH1 and IDH2 inhibitors have been approved for targeted therapy of acute myeloid leukemia. Clinical trials for solid tumors with IDH1 and IDH2 (IDH1/2) mutations are ongoing. Reports of IDH1/2-mutated non-small cell lung cancers (NSCLCs), however, are limited. METHODS: We evaluated IDH1/2 mutations in 1,924 NSCLC specimens (92% adenocarcinoma) using a next-generation sequencing assay....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.